Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1776-260X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis ; volume:17 ; number:6 ; day:22 ; month:10 ; year:2022 ; pages:643-653 ; date:11.2022
Targeted oncology ; 17, Heft 6 (22.10.2022), 643-653, 11.2022

Creator
Niizeki, Takashi
Tokunaga, Takayuki
Takami, Yuko
Wada, Yoshiyuki
Harada, Masaru
Shibata, Michihiko
Nakao, Kazuhiko
Sasaki, Ryu
Hirai, Fumihito
Shakado, Satoshi
Yoshizumi, Tomoharu
Itoh, Shinji
Yatsuhashi, Hiroshi
Bekki, Shigemune
Ido, Akio
Mawatari, Seiichi
Honda, Koichi
Sugimoto, Rie
Senju, Takeshi
Takahashi, Hirokazu
Kuwashiro, Takuya
Maeshiro, Tatsuji
Nakamuta, Makoto
Aratake, Yoshifusa
Yamashita, Tsutomu
Otsuka, Yuichiro
Matsumoto, Shuichi
Sohda, Tetsuro
Shimose, Shigeo
Murotani, Kenta
Tanaka, Yasuhito
Contributor
SpringerLink (Online service)

DOI
10.1007/s11523-022-00921-x
URN
urn:nbn:de:101:1-2023020409145668058731
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:55 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Niizeki, Takashi
  • Tokunaga, Takayuki
  • Takami, Yuko
  • Wada, Yoshiyuki
  • Harada, Masaru
  • Shibata, Michihiko
  • Nakao, Kazuhiko
  • Sasaki, Ryu
  • Hirai, Fumihito
  • Shakado, Satoshi
  • Yoshizumi, Tomoharu
  • Itoh, Shinji
  • Yatsuhashi, Hiroshi
  • Bekki, Shigemune
  • Ido, Akio
  • Mawatari, Seiichi
  • Honda, Koichi
  • Sugimoto, Rie
  • Senju, Takeshi
  • Takahashi, Hirokazu
  • Kuwashiro, Takuya
  • Maeshiro, Tatsuji
  • Nakamuta, Makoto
  • Aratake, Yoshifusa
  • Yamashita, Tsutomu
  • Otsuka, Yuichiro
  • Matsumoto, Shuichi
  • Sohda, Tetsuro
  • Shimose, Shigeo
  • Murotani, Kenta
  • Tanaka, Yasuhito
  • SpringerLink (Online service)

Other Objects (12)

Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort

Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: a comparative analysis in a European real-world cohort

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab

Immune Checkpoint Inhibitor-Related Pneumonia in Unresectable Hepatocellular Carcinoma: Two Fatal Cases under Atezolizumab plus Bevacizumab

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Related objects